BR112017004048A2 - formulações de pó inalável de oligômeros de alginato - Google Patents
formulações de pó inalável de oligômeros de alginatoInfo
- Publication number
- BR112017004048A2 BR112017004048A2 BR112017004048A BR112017004048A BR112017004048A2 BR 112017004048 A2 BR112017004048 A2 BR 112017004048A2 BR 112017004048 A BR112017004048 A BR 112017004048A BR 112017004048 A BR112017004048 A BR 112017004048A BR 112017004048 A2 BR112017004048 A2 BR 112017004048A2
- Authority
- BR
- Brazil
- Prior art keywords
- particles
- alginate oligomer
- phospholipid
- powder formulations
- inhalable powder
- Prior art date
Links
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 title abstract 2
- 229940072056 alginate Drugs 0.000 title abstract 2
- 235000010443 alginic acid Nutrition 0.000 title abstract 2
- 229920000615 alginic acid Polymers 0.000 title abstract 2
- 239000000843 powder Substances 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000002245 particle Substances 0.000 abstract 5
- 150000003904 phospholipids Chemical class 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010057190 Respiratory tract infections Diseases 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 239000007921 spray Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/734—Alginic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Otolaryngology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
a invenção fornece partículas secas por pulverização para inalação, as referidas partículas consistindo em (i) pelo menos cerca de 70% p/p de um oligômero de alginato, (ii) pelo menos cerca de 10% p/p, no total, de um fosfolipídeo e um composto antiaderente, em que o referido fosfolipídeo é sólido à temperatura ambiente, e em que o referido fosfolipídeo está presente em não menos de 0,5% p/p e o referido composto antiaderente está presente em não menos de 0,5% p/p, e (iii) não mais do que cerca de 10% p/p de outros excipientes. a invenção fornece ainda um novo método para a preparação das referidas partículas, cápsulas e inaladores de pó seco compreendendo as referidas partículas e a utilização terapêutica das referidas partículas, em particular no tratamento ou prevenção de uma infecção respiratória ou um distúrbio respiratório.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1415381.1A GB201415381D0 (en) | 2014-08-29 | 2014-08-29 | Inhalable powder formulations of alginate oligomers |
PCT/EP2015/069785 WO2016030524A1 (en) | 2014-08-29 | 2015-08-28 | Inhalable powder formulations of alginate oligomers |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017004048A2 true BR112017004048A2 (pt) | 2017-12-05 |
Family
ID=51752384
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017004048A BR112017004048A2 (pt) | 2014-08-29 | 2015-08-28 | formulações de pó inalável de oligômeros de alginato |
Country Status (13)
Country | Link |
---|---|
US (2) | US20180235879A1 (pt) |
EP (1) | EP3185853B1 (pt) |
JP (1) | JP6707076B2 (pt) |
KR (1) | KR102582982B1 (pt) |
CN (2) | CN113384538A (pt) |
AU (1) | AU2015308381B2 (pt) |
BR (1) | BR112017004048A2 (pt) |
CA (1) | CA2959101A1 (pt) |
DK (1) | DK3185853T3 (pt) |
FI (1) | FI3185853T3 (pt) |
GB (1) | GB201415381D0 (pt) |
RU (1) | RU2708397C1 (pt) |
WO (1) | WO2016030524A1 (pt) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3708564A1 (en) | 2005-12-28 | 2020-09-16 | Vertex Pharmaceuticals Incorporated | A solid form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
MX342288B (es) | 2010-04-22 | 2016-09-23 | Vertex Pharma | Proceso para producir compuestos de cicloalquilcarboxamido-indol. |
ES2957761T3 (es) | 2014-04-15 | 2024-01-25 | Vertex Pharma | Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quística |
EP3463378A4 (en) | 2016-06-03 | 2020-01-08 | Otitopic Inc. | DRY POWDER FORMULAS FOR INHALATION |
JP7366406B2 (ja) | 2017-01-03 | 2023-10-23 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 生分解性の抗菌性足場としての一酸化窒素放出性アルギン酸塩およびそれに関する方法 |
GB201702161D0 (en) * | 2017-02-09 | 2017-03-29 | Algipharma As | A companion diagnostic method for use in the treatment of cystic fibrosis with alginate oligomers |
WO2018178902A1 (en) | 2017-03-28 | 2018-10-04 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing polyaminoglycosides as biodegradable antibacterial scaffolds and methods pertaining thereto |
CA3091458A1 (en) | 2018-03-06 | 2019-09-12 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto |
US20210030891A1 (en) * | 2018-03-19 | 2021-02-04 | Algipharma As | Use of alginate oligomers to enhance the translocation of micro/nanoparticles across mucus layers |
US11421044B2 (en) | 2018-12-28 | 2022-08-23 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing antibacterial polymers and scaffolds fabricated therefrom and methods pertaining thereto |
CN111202723A (zh) * | 2020-02-15 | 2020-05-29 | 江苏艾立康药业股份有限公司 | 一种达芦那韦吸入干粉药物组合物及其制备方法 |
WO2021183371A1 (en) * | 2020-03-11 | 2021-09-16 | Purdue Research Foundation | Nano-composite microparticles of polymyxin |
CN113491678B (zh) * | 2020-04-07 | 2023-01-20 | 知和(山东)大药厂有限公司 | 一种盐酸阿比朵尔吸入剂及其制备方法 |
CN116322647A (zh) | 2020-08-07 | 2023-06-23 | 科学和工业研究委员会 | 用于治疗急性呼吸窘迫综合征的微乳剂药物递送体系 |
WO2023003593A1 (en) * | 2021-07-20 | 2023-01-26 | Kenox Pharmaceuticals, Inc. | Pulmonary biguanide formulations |
WO2023028354A1 (en) * | 2021-08-26 | 2023-03-02 | Celestial Therapeutics, Inc | Method for generating dry powder suitable for inhalation/intranasal/intratracheal administration of antimicrobial phospholipid compositions |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991011205A1 (en) | 1990-01-23 | 1991-08-08 | Trancel Corporation | Mannuronic acid containing alginate wound healing composition and method |
US5169840A (en) | 1991-03-27 | 1992-12-08 | Nobipols Forskningsstiftelse | Diequatorially bound β-1, 4 polyuronates and use of same for cytokine stimulation |
NO305033B1 (no) | 1997-05-09 | 1999-03-22 | Algipharma As | Fremgangsmate for fremstilling av uronsyreblokker fra alginat |
AU1787800A (en) | 1998-12-08 | 2000-06-26 | Phares Pharmaceutical Research N.V. | Phospholipid compositions |
PL349885A1 (en) * | 1999-02-03 | 2002-09-23 | Max Delbrueck Ct F Molekulare | Compressed air inhaler for pulmonary application of liposomal powder aerosols and powder aerosols suitable therefor |
US6586008B1 (en) * | 1999-08-25 | 2003-07-01 | Advanced Inhalation Research, Inc. | Use of simple amino acids to form porous particles during spray drying |
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
NO326145B1 (no) | 2001-11-30 | 2008-10-06 | Fmc Biopolymer As | Fremgangsmate for a stimulere vektokning hos pattedyr, fugler og krypdyr. |
JP2006512102A (ja) * | 2002-04-11 | 2006-04-13 | メディミューン・ヴァクシンズ・インコーポレーテッド | 噴霧乾燥による生物活性材料の防腐 |
US20120321717A1 (en) * | 2003-04-14 | 2012-12-20 | Vectura Ltd. | Devices and pharmaceutical compositions for enhancing dosing efficiency |
CA2810655C (en) | 2004-06-24 | 2013-12-10 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
GB0515492D0 (en) * | 2005-07-28 | 2005-08-31 | Reckitt Benckiser Healthcare | Improvements in or relating to compositions,articles and methods |
GB2430881B (en) * | 2005-10-06 | 2010-10-13 | Ntnu Technology Transfer As | Oligoelectrolyte polyols for the treatment of mucosal hyperviscosity |
SI2395002T1 (sl) | 2005-11-08 | 2014-10-30 | Vertex Pharmaceuticals Incorporated | Farmacevtski sestavek, vsebujoč heterociklični modulator prenašalcev z ATP-vezavno kaseto |
ES2377840T3 (es) | 2006-05-12 | 2012-04-02 | Vertex Pharmaceuticals, Inc. | Composiciones de N-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquinolina-3-carboxamida |
GB0613161D0 (en) * | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
GB0707096D0 (en) | 2007-04-12 | 2007-05-23 | Ntnu Technology Transfer As | Method |
EP2222304A2 (en) | 2007-09-14 | 2010-09-01 | Vertex Pharmaceuticals Incorporated | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
ES2658064T3 (es) | 2007-11-16 | 2018-03-08 | Vertex Pharmaceuticals Incorporated | Moduladores de isoquinolina de transportadores de casete de unión a ATP |
WO2009068841A2 (en) * | 2007-11-27 | 2009-06-04 | Algipharma Ipr As | Use of alginate oligomers in combating biofilms |
EA201070699A1 (ru) | 2007-12-07 | 2011-02-28 | Вертекс Фармасьютикалз Инкорпорейтед | Композиции 3-(6-(1-2,2-дифторбензо[d][1,3]диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты |
PL2639223T3 (pl) | 2007-12-07 | 2017-09-29 | Vertex Pharmaceuticals Incorporated | Sposób wytwarzania kwasów cykloalkilokarboksyamido-pirydyno-benzoesowych |
US20100036130A1 (en) | 2007-12-07 | 2010-02-11 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
SI2225230T1 (sl) | 2007-12-07 | 2017-03-31 | Vertex Pharmaceuticals Incorporated | Trdne oblike 3-(6-(1-2,2-difluorobenzo(d)(1,3)dioxol-5-il)ciklopropan- karboksamido)-3-metilpiridin-2-il) benzojske kisline |
WO2009094846A1 (fr) * | 2007-12-28 | 2009-08-06 | Shanghai Institute Of Pharmaceutical Industry | Inhalation d'une poudre à base d'insuline nasale |
EP2328618B1 (en) | 2008-08-13 | 2017-11-29 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4- oxoquinoline-3-carboxamide and administration thereof |
WO2010037066A2 (en) | 2008-09-29 | 2010-04-01 | Vertex Pharmaceuticals Incorporated | Dosage units of 3-(6-(1-(2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
SI2349263T1 (sl) | 2008-10-23 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Modulatorji cistiäśno-fibroznega transmembranskega regulatorja prevodnosti |
NZ609962A (en) | 2008-11-06 | 2014-11-28 | Vertex Pharma | Modulators of atp-binding cassette transporters |
UA104876C2 (uk) | 2008-11-06 | 2014-03-25 | Вертекс Фармасьютікалз Інкорпорейтед | Модулятори atф-зв'язувальних касетних транспортерів |
WO2010139957A1 (en) * | 2009-06-03 | 2010-12-09 | Algipharma Ipr As | Alginate oligomers for use in overcoming multidrug resistance in bacteria |
EP2813227A1 (en) | 2009-10-22 | 2014-12-17 | Vertex Pharmaceuticals Incorporated | Compositions for treatment of cystic fibrosis and other chronic diseases |
JP2013523833A (ja) | 2010-04-07 | 2013-06-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | 3−(6−(1−(2,2−ジフルオロベンゾ[d][1,3]ジオキソール−5−イル)シクロプロパンカルボキサミド)−3−メチルピリジン−2−イル)安息香酸の医薬組成物およびその投与 |
CN102933206A (zh) | 2010-04-07 | 2013-02-13 | 弗特克斯药品有限公司 | 3-(6-(1-(2,2-二氟苯并[d][1,3]二氧杂环戊烯-5-基)环丙烷甲酰胺基)-3-甲基吡啶-2-基)苯甲酸的固体形式 |
WO2011133956A1 (en) | 2010-04-22 | 2011-10-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
AU2011242452A1 (en) | 2010-04-22 | 2012-11-08 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
CA2796602A1 (en) | 2010-04-22 | 2011-10-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
MX342288B (es) | 2010-04-22 | 2016-09-23 | Vertex Pharma | Proceso para producir compuestos de cicloalquilcarboxamido-indol. |
NZ603386A (en) | 2010-05-20 | 2015-02-27 | Vertex Pharma | Pharmaceutical compositions and administrations thereof |
CN102302477B (zh) * | 2011-06-02 | 2013-08-28 | 张振海 | 一种华蟾酥毒基干粉吸入剂及其制备方法、应用 |
KR102240042B1 (ko) * | 2012-05-03 | 2021-04-14 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 상기도 감염 치료용 폴리이노신산-폴리사이티딜산(폴리 (i:c)) 제형 |
KR20160119259A (ko) | 2014-02-28 | 2016-10-12 | 알지파마 에이에스 | 낭포성 섬유증 및 cftr 이온 채널의 기능 결함과 관련된 기타 병태의 치료제로서 알기네이트 올리고머의 용도 |
-
2014
- 2014-08-29 GB GBGB1415381.1A patent/GB201415381D0/en not_active Ceased
-
2015
- 2015-08-28 CA CA2959101A patent/CA2959101A1/en active Pending
- 2015-08-28 BR BR112017004048A patent/BR112017004048A2/pt not_active IP Right Cessation
- 2015-08-28 EP EP15763236.5A patent/EP3185853B1/en active Active
- 2015-08-28 DK DK15763236.5T patent/DK3185853T3/da active
- 2015-08-28 KR KR1020177006232A patent/KR102582982B1/ko active IP Right Grant
- 2015-08-28 CN CN202110642947.2A patent/CN113384538A/zh active Pending
- 2015-08-28 FI FIEP15763236.5T patent/FI3185853T3/fi active
- 2015-08-28 CN CN201580046086.4A patent/CN106659689B/zh active Active
- 2015-08-28 AU AU2015308381A patent/AU2015308381B2/en active Active
- 2015-08-28 WO PCT/EP2015/069785 patent/WO2016030524A1/en active Application Filing
- 2015-08-28 US US15/507,712 patent/US20180235879A1/en not_active Abandoned
- 2015-08-28 JP JP2017511704A patent/JP6707076B2/ja active Active
- 2015-08-28 RU RU2017106950A patent/RU2708397C1/ru active
-
2021
- 2021-08-20 US US17/445,577 patent/US11992553B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
GB201415381D0 (en) | 2014-10-15 |
EP3185853A1 (en) | 2017-07-05 |
JP2017530952A (ja) | 2017-10-19 |
AU2015308381A1 (en) | 2017-04-06 |
KR20170044670A (ko) | 2017-04-25 |
US20210386666A1 (en) | 2021-12-16 |
DK3185853T3 (da) | 2024-02-26 |
KR102582982B1 (ko) | 2023-09-25 |
CN106659689B (zh) | 2021-07-13 |
JP6707076B2 (ja) | 2020-06-10 |
AU2015308381B2 (en) | 2020-10-22 |
US11992553B2 (en) | 2024-05-28 |
RU2708397C1 (ru) | 2019-12-06 |
CN106659689A (zh) | 2017-05-10 |
CN113384538A (zh) | 2021-09-14 |
FI3185853T3 (fi) | 2024-02-22 |
US20180235879A1 (en) | 2018-08-23 |
WO2016030524A1 (en) | 2016-03-03 |
EP3185853B1 (en) | 2024-01-31 |
CA2959101A1 (en) | 2016-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017004048A2 (pt) | formulações de pó inalável de oligômeros de alginato | |
MX2022004103A (es) | Una formulacion de rapamicina inhalable para tratar afecciones relacionadas con la edad. | |
BR112015021814A2 (pt) | aglomerados respiráveis de partículas carreadoras porosas e fármaco micronizado | |
BR112017010551A2 (pt) | composto, métodos para ativação de guanilato ciclase solúvel, para tratamento de uma ou mais condições selecionadas a partir de uma doença em um paciente e para tratamento de uma doença ou condição, composição farmacêutica, uso de um composto, e, medicamento. | |
BR112019001141A2 (pt) | compostos diaza-heterobicíclicos substituídos e uso dos mesmos | |
MX2019003397A (es) | Metodos para tratar trastornos mitocondriales y metabolicos. | |
MX2015010829A (es) | Compuestos terapeuticos y sus usos. | |
MY186229A (en) | A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic | |
BR112017006842A2 (pt) | formulação de rapamicina inalável para o tratamento de hipertensão pulmonar | |
MX2016009231A (es) | Administracion de tasimelteon en condiciones de ayuno. | |
MX2017009122A (es) | Inhalador de polvo seco con propionato de fluticasona y xinafoato de salmeterol. | |
ZA202104378B (en) | Dry powder inhalation formulation and its use for the therapeutic treatment of lungs | |
MX2016016201A (es) | Particulas inhalables que comprenden una combinacion de un anticolinergico, un corticosteroide y un beta-adrenergico. | |
BR112016024488A2 (pt) | compostos de ciclo-hexenila, composições que compreendem esses e o uso dos mesmos | |
EP3877383A4 (en) | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY DISEASES | |
BR112017003731A2 (pt) | composições e métodos para prevenir ou tratar doenças, condições ou processos distinguidos por proliferação anormal de fibroblasto e deposição de matriz extracelular | |
PH12015502203A1 (en) | Phenyl derivative | |
BR112017014861A2 (pt) | ?combinação e composição farmacêuticas, inalador de pó seco, uso de uma combinação farmacêutica, e, método para tratamento de um distúrbio pulmonar? | |
BR112017003888A2 (pt) | método de fabricação de uma formulação de pó seco, formulação, inalador de pó seco, uso de partículas comoídas por jatos e cocondicionadas, e, kit farmacêutico. | |
PT3257516T (pt) | Composição farmacêutica compreendendo cetraria islandica ach., hialuronato de sódio e uma solução salina para tratamento de doenças do sistema respiratório | |
PH12017500323A1 (en) | P38 map kinase inhibiting indanyl urea compounds | |
IN2014MN02133A (pt) | ||
BR112018070521A2 (pt) | processo para preparação de formulações sólidas de mesalazina | |
WO2016016820A3 (en) | Anionically modified n-sulfonic polyallylamine derivative, pharmaceutical composition comprising the n-sulfonic polyallylamine derivative as the active substance and use of said derivate for the production of a medicine | |
AR098868A1 (es) | Composición farmacéutica en polvo seco para inhalación |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2737 DE 20/06/2023. |